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Abstract
Vasodilatory shock frequently occurs after cardiac surgery, particu-
larly after cardiac assist device implantation. This complication is 
often associated with high mortality, especially if refractory to con-
ventional vasoconstrictor treatment. Methylene blue, a guanylate 
cyclase inhibitor, has been successfully used in the management 
of vasodilatory shock associated with cardiopulmonary bypass. We 
present four successive cases after implantation of cardiac assist 
devices suffering from norepinephrine and vasopressin refractory 
severe vasodilatory shock. In all patients, administration of a single 
dose of methylene blue (2 mg/kg body weight) resulted in an imme-
diate and persistent decrease in vasoconstrictor dosages and serum 
lactate concentrations. Despite of this benefit, all patients deceased 
during hospital stay, however, this was not related to the methylene 
blue treatment. Methylene blue seems to be a promising therapeuti-
cal option in patients with otherwise resistant vasodilatory shock 
after cardiac assist device implantation. However, controlled clini-
cal trials are necessary to substantiate safety and efficacy.
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Introduction
Vasodilatory shock is a frequent complication in the postop-
erative period in patients undergoing cardiac surgery which 
increases morbidity and mortality. It is characterized by pe-
ripheral vasodilatation, severe hypotension and by a poor 
response  to  therapy  with  vasoconstrictors.  One  important 
pathophysiological facet of this disease is an increased syn-
thesis of nitric oxide [1, 2]. The use of the guanylate cyclase 
inhibitor methylene blue has been shown to be a success-
ful therapeutical option in vasoplegic cardiac surgical pa-
tients undergoing coronary artery bypass surgery or valve 
replacement [3]. After implantation of cardiac assist devices, 
the incidence of vasodilatory shock has been described to 
be excessively high [4]. We report four successive patients 
after cardiac assist device implantation with catecholamine 
refractory vasoplegia, who were successfully treated with a 
single dose of methylene blue without any immediate seri-
ous side effects.
Case Report
All patients received a single dose infusion of methylene 
blue (2 mg/kg body weight intravenously) over 30 minutes.
Case 1
A 49-year-old male patient (188 cm, 98 kg) suffered from 
decompensated dilative cardiomyopathy. As he did not re-
spond to conventional treatment (inotropes and insertion of 
an intraaortic balloon pump) a Jarvik 2000 left ventricular 
assist device (Jarvik Heart Inc., NYC, NY, USA) was im-
planted. Postoperatively, the patient developed right heart 
failure, necessitating the implantation of an additional tem-
porary right ventricular assist device (Levitronix, Levitronix 
GmbH, Zurich, Switzerland). Severe postoperative bleed-
ing required rethoracotomy and mass transfusion. Despite 
no further bleeding and faultless function of both cardiac 
assist  devices,  the  patient  developed  a  severe  vasoplegic 
shock, requiring very high dosages of norepinephrine (4.0 
mg/h) and vasopressin (6.0 I.U./h). After administration of 
a single dose methylene blue both norepinephrine and vaso-
pressin dosages rapidly decreased and serum lactate concen-
trations normalized (Fig. 1). On the fourth postoperative day 
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the patient developed pneumonia caused by pseudomonas 
aeruginosa with severe impairment of pulmonary function. 
An oxygenator was connected to the right ventricular assist 
device to enable sufficient oxygenation. Despite inhalative 
application of milrinone and iloprost, right ventricular func-
tion did not recover sufficiently. Although the patient was 
treated with antibiotics (piperacillin/tazobactam, ciprofloxa-
cin, vancomycin) markers of infection did not decrease and 
the patient died ten days after methylene blue administration 
from multi-organ failure.
Case 2
A 46-year-old male patient (185 cm, 80 kg) with a history 
of myocardial infarction and limited cardiac function (LVEF 
20%) underwent resection of a massive left ventricular ante-
rior wall aneurysm combined with mitral valve annuloplasty. 
Despite adequate filling pressures, use of multiple inotropic 
agents including levosimendan and insertion of an intraaor-
tic balloon pump, cardiogenic shock occured postoperative-
ly. He was transferred to the operating room for venoarterial 
extracorporal membrane oxygenation (ECMO, Medtronic, 
Biomedicus, MI, USA) rescue therapy. Since weaning from 
ECMO remained unsuccessful for four days, a permanent 
left  ventricular  assist  device  (Jarvik  2000)  was  inserted. 
Postoperatively, the patient suffered from right heart fail-
ure resistant to inhalation of iloprost and milrinone, so that 
venoarterial ECMO had to be re-implanted. Despite good 
Figure 1. Individual and median values of mean arterial blood pressure (panel A), norepinephrine dosage (panel B), vasopressin 
dosage (panel C), and serum lactate concentration (panel D) before (B) and 1, 2, 3, 4, 5, 12, and 24 hours after a single dose admin-
istration of methylene blue (2 mg/kg body weight).
212                                                                                                                                                                                                                                                                                                                                                                                                                                             213J Clin Med Res  •  2012;4(3):212-215    Use of Methylene Blue
Articles © The authors   |   Journal compilation © J Clin Med Res and Elmer Press™   |   www.jocmr.org
function of both cardiac assist devices the patient suffered 
from  severe  vasodilatory  shock  resistant  to  high  dosages 
of norepinephrine (3.0 mg/h) and vasopressin (8.0 I.U./h). 
Administration of methylene blue resulted in a reduction of 
norepinephrine and vasopressin to acceptable dosages within 
four hours (Fig. 1). However, no therapeutic option was suit-
able for this patient: switching to a synchronized biventricu-
lar assist device was technically not possible any more. The 
patient died 18 hours after methylene blue administration. 
Case 3
In a 32-year-old male patient (187 cm, 114 kg) with de-
compensated dilative cardiomyopathy a biventricular assist 
device  (Berlin  Heart  Excor,  Berlin  Heart  GmbH,  Berlin, 
Germany) was implanted, as a bridge to transplant. Postop-
eratively, severe septic shock caused by pneumonia occurred 
and was treated empirically with meropenem, moxifloxacin, 
and linezolid. Despite adequate filling pressures, 7.0 mg/h of 
norepinephrine and 7.0 I.U./h of vasopressin were necessary 
to stabilize circulatory conditions. Methylene blue was ap-
plicated and vasoconstrictor dosages could be reduced with-
in hours (Fig. 1). On the fourth postoperative day the patient 
suddenly developed pulmonary edema. Despite therapeuti-
cal heparinization and aspirin therapy echocardiography re-
vealed a thrombus, most probably derived from the left atrial 
appendage, nearly completely occluding the left ventricular 
inflow cannula. In an immediate re-operation the left ven-
tricular inflow cannula was replaced from the left ventricular 
apex to the left atrium. During surgery, the left atrium rup-
tured. Surgical repair was unfeasible, so that the patient died 
intraoperatively from severe hemorrhage.
Case 4
A 70-year-old male patient (155 cm, 64 kg) with pre-exist-
ing coronary heart disease underwent coronary angiography 
with instable angina pectoris. A significant stenosis of the 
right coronary artery was detected. The attempt to insert the 
wire into the right coronary artery resulted in a complete 
dissection of the vessel. Emergency coronary artery bypass 
operation with a saphenous vein graft was performed im-
mediately, but revascularisation was technically impossible. 
Accordingly, the patient developed right heart failure and re-
ceived venoarterial ECMO. Postoperatively, norepinephrine 
(1.6 mg/h) and vasopressin (8.0 I.U. /h) resistant vasodila-
tory shock occurred. After a single dose of methylene blue 
vasoconstrictor dosages decreased within hours (Fig. 1). De-
spite maximum pharmacological support including inhala-
tion of iloprost and milrinone right ventricular performance 
could not be improved during the following seven days. As 
the patient was considered to be too old for implantation of 
a definitive right ventricular assist device, therapeutic mea-
sures were terminated. The patient died 8 days after methy-
lene blue administration.
Discussion
  
The present case series shows that intravenous single dose 
administration of methylene blue in patients with vasodila-
tory shock after cardiac assist device implantation resulted 
in improved hemodynamics. An immediate and persistent 
decrease  of  vasopressor  (norepinephrine  and  vasopressin) 
dosages was observed in all patients. Moreover, the lower 
lactate levels after infusion suggest that methylene blue in-
creased the vascular tone without compromising global tis-
sue perfusion (Fig.1).
One underlying mechanism of vasodilatory shock in-
volves increased nitric oxide production. The release of nitric 
oxide leads to activation of the enzyme guanylate cyclase, 
which increases the synthesis of cGMP, a mediator of vas-
cular smooth muscle relaxation [1]. Methylene blue inhibits 
guanylate cyclase, thus, mitigating the vasorelaxant effect of 
nitric oxide in the smooth muscle cells of the vessels [2, 5].   
At the time point of methylene blue administration all 
patients were severely ill with multiple organ failure and 
high Apache II scores ranging between 32 and 40 with a 
predicted mortality between 76% and 91% [6]. Despite the 
beneficial effects on hemodynamics and serum lactate con-
centrations all patients died during hospital stay. However, 
this was not related to methylene blue administration. At a 
dosage of 2 mg/kg body weight no serious side effects were 
observed. The only adverse effects were discolouration of 
the urine (greenish-blue) in all four patients and shivering in 
one patient (patient 2). 
We conclude that methylene blue, through its effect on 
the nitric oxide pathway, is a promising option in the treat-
ment of patients with vasodilatory shock after cardiac assist 
device implantation. However, a controlled clinical trial is 
needed to evaluate the benefit and best time point of applica-
tion of methylene blue in severely ill patients before routine 
use can be recommended.
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